Propofol EDTA and reduced incidence of infection

Anaesthesia and Intensive Care

Volumn 34, Issue 3, 2006, Pages 362-368

  Jansson, J R ^a   Fukada, T ^b   Ozaki, M ^b   Kimura, S ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c AIDS Clinical Center   (Japan)

Author keywords

Anaesthesia; Extrinsic contamination; Nosocomial infection; Postoperative infection; Propofol; Sedation

Indexed keywords

BENZYL ALCOHOL; CHLORBUTOL; CHLOROCRESOL; EDETIC ACID; LIPID; PHENOL; PHENYLMERCURIC ACETATE; PHENYLMERCURIC NITRATE; PROPOCAM; PROPOFOL;

ACINETOBACTER CALCOACETICUS; ASEPSIS; CANDIDA ALBICANS; CLINICAL PRACTICE; DRUG FORMULATION; ECONOMIC EVALUATION; ENTEROBACTER AEROGENES; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INCIDENCE; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MICROBIAL CONTAMINATION; MICROBIAL GROWTH; MORBIDITY; MORTALITY; NONHUMAN; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; REVIEW; RISK ASSESSMENT; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 33745672054     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0603400305     Document Type: Review

References (20)

1. Bach A, Motsch J. Infectious risks associated with the use of propofol. Acta Anaesthesiol Scand 1996; 40:1189-1196.
2. Hart B. 'Diprivan': a change in formulation. Eur J Anaesthesiol 2000; 17:71-73.
3. Han J, Davis S, Washington C. Comparative stability of propofol with disodium. edetate versus Sulfite-containing propofol. Am J Anesthesiology 2000; 27 (6S) suppl:16-18.
4. Code of Federal Regulations Title 21, Volume 4 Revised as of April 1, 2005. CITE: 21CFR201.22.
5. Bobey DG, Russell AD, Jones CB. Selection of disodium edetate as the optimal antimicrobial additive for use in propofol emulsion. Pharmacol Ther 2000; 25:589-603.
6. Soong WAL. Bacterial contamination of propofol in the operating theatre. Anaesth Intensive Care 1999; 27:493-496.
7. McHugh GJ, Roper GM. Propofol emulsion and bacterial contamination. Can J Anaesth 1995; 42:801-804.
8. Webb SAR, Roberts B, Breheny FX, Golledge CL, Cameron PD, Van Heerden PV. Contamination of propofol infusions in the intensive care unit: incidence and clinical significance. Anaesth Intensive Care 1998; 26:162-164.
9. Henry B, Plante-Jenkins C, Ostrowska K. An outbreak of Serratia marcescens associated with the anesthetic agent propofol. Am J Infect Control 2001; 29:312-315.
10. Massari M, Petrosillo N, Ippolito G et al. Transmission of hepatitis C virus in a gynecological surgery setting. J Clin Microbiol 2001; 39:2860-2863.
11. McNeil MM, Lasker BA, Lott TJ, Jarvis WR. Postsurgical Candida albicans infections associated with an extrinsically contaminated intravenous anesthetic agent. J Clin Microbiol 1999; 37:1398-1403.
12. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs and attributable mortality. JAMA 1994; 271:1598-1601.
13. Noriega RL, Angulo GB, Alalorre MAM, Molina LR, Torres NPC. Extrinsic bacterial contamination of propofol. (Spanish). Rev Mex Anest 1999; 22:59-67.
14. Fukada T, Ozaki M. Bacterial growth in two propofol formulations recently used in Japan. Life Support and Anesthesia (LISA) 2004:11:1174-1175.
15. Hajjar J, Girard R. Surveillance of nosocomial infections associated with anaesthesia. A multicentre study. (French). Ann Fr Anesth Reanim 2000; 19:47-53.
16. AstraZeneca data on file (AstraZeneca, Macclesfield, U.K.).
17. Ovechkin AM, Gagarina IuV. Diprivan EDTA - the choice in favour of patient's safety. (Russian). Anesteziol i Reanimatol 2002; 3:52-56.
18. Rebollo MH, Bernal JM, Llorca J, Rabasa JM, Revuelta JM. Nosocomial infections in patients having cardiovascular operations: A multivariate analysis of risk factors. J Thorac Cardiovasc Surg 1996; 112:908-913.
19. Christiansen B, Kirchhefer R, Gundermann KO. Hygienic monitoring of environmental surroundings in office-based ambulatory surgery units - an instrument for infection control. Zbl Hyg Umweltmed 1999; 202:363-375.
20. Kimura S. Prevention of nosocomial infection and cost benefits. (Japanese). The Japanese Journal of Clinical and Experimental Medicine 2004; 81:1086-1089.